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Nearlyone-
halfofpatientswithcryptogenicstrokehaveapatentforamenovale(PFO).Thedilemmaofwhethertoclose 
thesePFOspercutaneously,inanefforttoreducetheriskofrecurrentparadoxicalembolism,hasbeenamatterofongoing
debateformorethanadecade.Earlyrandomizedclinicaltrialsfailedtodemonstrateasigniﬁcantbeneﬁtofpercuta
neous PFOclosureforsecondarypreventionofcryptogenicstrokeinanintention-to-treatanalysis.Thelong-
termfollow-updata from the RESPECT trial and 2 new randomized trials (CLOSE and REDUCE) have clariﬁed 
theseﬁndings. They showed that with good patient selection, transcatheter PFO closure 
signiﬁcantly reduces the risk of recurrent stroke compared with medical therapy in patients with
cryptogenic stroke, with no increased risk of serious adverse events or inﬂuence on major 
bleeding. (J Am Coll Cardiol 2018;71:1035–43) © 2018 by the American College of 
JOURNALO FT HEA MERICANCOLLEGEO FC ARDIOLOGY VOL.71, NO.9,2 018
ª201 8 BY TH E A MERICA N C OLL E G E O F CA RDIOL O G Y FOU N D A T I ON P U 
BLIS HED B Y E L S EVIER
REVIEW TOPIC OF THE WEEK
Cryptogenic Stroke and
Patent Foramen Ovale
Mohammad K. Mojadidi, MD,aMuhammad O. Zaman, MD,aIslam Y. Elgendy, MD,aAhmed N. Mahmoud, 
MD,aNimesh K. Patel, MD,bNayan Agarwal, MD,cJonathan M. Tobis, MD,dBernhard Meier, MDe
heprevalenceofpatent  foramen
ovale(PFO)is20%to
25%intheadultpopulation.Inpeo-ple
whosufferacryptogenic stroke,40%to
50%ofpatients  haveaPFO(1–
3).Ahypermobileseptum primum,  referredto  as
anatrial  septalaneu-
rysm,associatedwithaPFOhasbeenfoundtoincrea
se  the  riskofaninitial  stroke(meta-
analysisof4studies:
oddsratio[OR]:4.96;95%conﬁdenceinterval[CI]:
2.37to10.39)andrecurrentstroke(OR:23.93;95%CI:
3.09to185.42).  Changesinvolume  and
pressureofthe  right  atrium
leadtomomentsofpatencyofthefo-ramen
ovale.Anatrial  septal  aneurysm  may
openthePFO  with  every  heartbeat,  thereby
increasingthepo-tential  for  passageofthrombus
fromthevenousto  arterial  system(3–5).Asimilar
effectisexertedby  aEustachian   valve(6)
(oraChiari  network),which
directs bloodﬂow from the inferior vena cava to 
the fo- ramen ovale, as depicted inFigure 1.
Previous  trials  have  shown  thatinpatients
with  cryptogenic  stroke,theriskofrecurrent
strokeishigh,  withnoclear-cut
differenceinefﬁcacybetweenantiplateletandoral
anticoagulation  therapywithwarfarinornovel
oralanticoagulants,intheabsenceofatrialﬁbrillati
on(7–9).Ameta-analysisof48observational
comparative  studies(n¼10,327)demonstrated
that  patients  with   cryptogenic
strokeortransient  ischemic  attack
(TIA)whoreceivedmedical  therapy  hada6.3-fold
increased  rateofrecurrent
neurologicaleventscomparedwithpatientswhoun
derwent  percutaneousPFOclosure(10).  Ran-
domized  clinical  trials  were
performedtodetermineunequivocallyifpercutane
ousPFOclosureissuperior
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AND A CRO N Y M S
tomedical therapy for secondary 
preventionofcryptogenic stroke 
(Table1).
DIAGNOSISANDQUANTIFICATIONOFPFO
(NMT  Medical,  Boston,  Massachusetts)
itself.Thedevice  was  associated  withahigher
thanexpectedrateofatrialﬁbrillation.Atotalof26p
atientsdevel-
FDA= Food  andDrug                                                                                                       
Administration oped atrialﬁbrillation; 23 occurred in the device 
arm, and 3 of these 26 patients had recurrent 
stroke. In
PFO= patent foramen ovale
TEE= transesophageal 
echocardiography
TIA= transient ischemic 
attack
Aright  heart  catheterization,  withdemon-
strationof  aguidewire
crossingtheseptum,isthemost  accurate
methodforconﬁrmingthepresenceofaPFO
.Transesophageal
addition,  of  patients  randomized  to  the  device
arm,  14%  had  relevant  residual  right-to-left
shunting  on  6-  month  follow-up
echocardiography. However, an as-
echocardiography (TEE) with bubble study is the
accepted noninvasive standard for diagnosing a
PFO,  allowing  quantiﬁcation  of  shunt  size,
documentation of anatomic PFO characteristics,
and  differentiation  among  PFO,  atrial  septal
defect, and pulmonary shunt(11,12). Transcranial
Doppler  is  more  sensitive  but  less  speciﬁc
because of its inability to differentiate be- tween
cardiac  and  pulmonary  shunting;  it  carries  a
sensitivity of  97% and speciﬁcity of  93% when
compared  with  TEE  bubble  study(13).
Transthoracic echocardiography has a sensitivity
of 46%, with improvement in sensitivity of up to
90%  when  per-  formed  with  harmonic
imaging(14–16).  If  a  PFO  is  suspected,  some
centers  prefer  an  initial  screening  with
transcranial  Doppler,  followed  by  TEE(17,18).
Angiographic  documentation  or  exclusion  of  a
PFO  can  be  performed  in  case  a  cardiac
catheterization  is  mandated  for  another
reason(19).
FIRST 3 RANDOMIZED TRIALS
CLOSUREITRIAL.CLOSUREI(Evaluationofthe
STARFlex  Septal  Closure  SysteminPatients
withaStroke  and/orTransientIschemic  Attack
duetoPresumedParadoxicalEmbolism
throughaPatent  Foramen
Ovale;NCT00201461)was  theﬁrstrandom-ized,
multicenter,  open-label  trial  (with blindedadju-
dicationofoutcome  events)toevaluatethe
efﬁcacy  and
safetyofpercutaneousPFOclosur
e  plusmedical  therapy
(aspirin,warfarin,orboth)compa
redwith  medical  therapy  alone
for  secondary
preventionofstrokeorTIA.Atotalo
f909patients,18  to
60yearsofage, with cryptogenic
strokeorTIA  who  hadaTEE-
conﬁrmedPFO were included.At
a2-year  follow-up,theprimary
composite  endpointofstroke,
TIA,anddeath
occurredin5.5%ofpatientsinthe
device
armand6.8%inthemedical
therapy
arm(p¼0.37).Inaddition,  PFO
closure  didnotsigniﬁcantly
reducetheincidenceofrecurrent
stroke  (2.9%  vs.
3.1%;p¼0.79)orTIA(3.1%  vs.
4.1%;p¼0.44).Deviceclosure
demonstratedasigniﬁcantly
higher   rateofmajor
vascularcomplications(3.2%
vs.0%)andatrialﬁbril-
lation(5.7%vs.0.7%)at2years(p<0.00
1forboth)(20).Inconsistencies
between CLOSUREIandprevious
Author's Personal 
Copyobservational  studies  have  been
attributedtoprob- lems    with    the    STARFlex
septal    closuredevice
sociation between residual shunting and recurrent
stroke has not been documented in randomized
trials  and  some  previous  observational
studies(21,22).
PCTRIAL.PC(Randomized  Clinical  TrialComparing
the  EfﬁcacyofPercutaneous
ClosureofPatentFora-menOvale  [PFO]  With
Medical  TreatmentinPatientsWith  Cryptogenic
Embolism;NCT00166257)wasarandomized,
multicenter,  open-label  (withblinded
adjudicationofoutcomeevents),
trialincluding414
patients (age<60years) with cryptogenic 
stroke,TIA
with  pathological  cerebral
imaging,oraperipheral  thromboembolic
event,who  had  PFO(23).  Patients  were
randomizedtotranscatheter  PFO
closurewiththeAmplatzerPFOOccluder(Abbott,C
hicago,Illinois)  versus  medical  therapy  with
antiplateletororal  anti-coagulant
treatment.Thetrialdemonstratednosig-
niﬁcantadvantageofPFOclosureovermedicalther
apyintheprimary
endpointofdeath,nonfatalstroke,
TIA,orperipheral  embolism  (3.4%  vs.
5.2%;p ¼0.34)at4-year  follow-up.  Separately,
therewasnostatistical superiorityofclosure when
comparing  ratesofnonfatal  stroke  (0.5%  vs.
2.4%;p¼0.14)  andTIA(2.5%  vs.  3.3%;p¼0.56,
respectively).Theincidenceofatrialﬁbrillation
was  not  signiﬁcantly  increased  after  closure
(2.9%  vs.  1.0%;p¼0.16).Noadverse
eventsorthromboses  occurred  that
couldbeattrib-utedtothedevice.
Amajor
limitationofthePCtrialwasthatitwasstatistically
underpoweredandpronetotypeIIerror.Also,
inclusionofpatients  with
noncerebralsystemicembolisms  madethestudy
group  different  from
thoseinmostobservationalstudies.
Moreover,theclinicalpresentationofTIAcan
besimilartotransient  neurologicaldeﬁcits
experiencedinmigraineaura;additionofthese
patientsmayhave  resultedinin-clusionofpatients
with  symptoms  unrelatedtothePFO,although
pathological  cerebralimaging  hadtobepresent.
Finally,  lackofblinding  and  regularon-site
auditsmayhave  resultedinundocumentedoff-
label  useofPFOoccluding
devicesinthemedicaltherapy arm(24,25).
RESPECT  TRIAL.RESPECT   (RandomizedEvaluation
ofRecurrent  Stroke
ComparingPFOClosuretoEstablished  Current
StandardofCareTreatment;NCT00465270)wasar
andomized, multicenter,open-label   trial   (with
blindedadjudicationofoutcome
JACCVOL.71,NO.9 ,2018 Mojadidietal.
MARCH6 ,2018:10 35 –43 Stroke   
andPFO
1037
Author's Personal 
Copy
events).Itwasevent-
drivenandincludedpatients18to  60yearsofage
with cryptogenic stroke who hadaTEE-proven
PFO.Atotalof980  patients  were  ran-
domizedtoclosure  withaPFOoccluderofthe
type
usedinPCormedicaltherapywithaspirin,warfarin
,clopidogrel,oraspirinplusdipyridamole.Selecti
onof  theappropriate  medical
therapywaslefttothediscretionoftheneurologist
.  Although
initialresultsoftheRESPECTtrialat2.6±2.0years
offollow-up
(26)onlyshowedanonsigniﬁcant
differenceinrecurrent  strokeintheintention-to-
treat  analysis  (0.7% vs.1.4%;p¼0.08)(26),  the
long-term(median
5.9years) follow-up data demonstrated that PFO
closure  signiﬁcantly
reducedtheincidenceofrecur-rent  stroke
compared with medical therapy (3.6%vs.5.8%;
hazard  ratio  [HR]:  0.55;95%CI:
0.31to0.999;p¼0.046)(27).Inaddition,  the
extendedfollow-
upresultsofRESPECTshowedahighly  signiﬁcant
62%  relative  risk  reduction  for  recurrent
strokeofun-  knownetiologyinfavorofclosure.
Reductionofstroke  was  enhancedinthose
withanatrialseptalaneurysm  (1.7%  vs.  7.6%;
HR:  0.20;95%  CI:0.06to0.70;p¼0.005,
interactionp¼0.04)andlargeshunt(2.0%   vs.
6.9%;HR:0.26:  95%  CI:  0.10to0.71;p¼0.005;
interactionp¼0.04).  Therewasnosig-niﬁcant
differenceinrateofserious  adverse  events,
atrialﬁbrillation,ormajor  bleeding  betweenthe2
groups (p>0.10 for all).
Despitethepresenceof  3patients
randomizedtotheclosurearm  who  hadrecurrent
strokesbuthadnotreceived  devices,thelong-
termintention-to-treat  follow-updata
fromRESPECTshowed  that  percuta-  neous  PFO
closures  reducetheincidenceofrecurrentstroke
compared  with  medical  therapyinpatientswith
cryptogenic  stroke.Inaddition,  the  trial  identi-
ﬁedplausible  subsetsofpatientswhobeneﬁt   the
most  fromPFOclosure  (i.e.,  patients  with atrial
septalaneurysmorlargeshunts).
All  theearlier  trials  were
limitedbyslowpatientrecruitment,
whichmayatleast  partlybeexplainedbypatient
reluctancetoundergorandomizationbecauseofpe
rsonal  preferenceforeither
closureormedicaltherapy.  This  also  may
havepotentiatedtheuseofoff-label PFO occluding
devicesinthose  pa-  tients
randomizedtothemedical  therapy
arm,andmayhave  resultedinpredominantly  low-
riskpatientsinthetrials.
META-ANALYSISOFFIRST3RANDOMIZEDTRIALS
Anumberofmeta-analysesofthe  earlier  PFOandstroke
trials(CLOSUREI,PC,  and
RESPECT)wereconductedinanefforttoincreasethe  sample  size
and reduce  the  riskoftypeIIerror(28,29).Onestudy
Author's Personal 
Copy
FIGURE 1PFO by Fluoroscopy and TEE
A PFO is shown angiographically after device closure(left)and by 
transesophageal echocardiography in the same projection before device
closure(right). A contrast medium injection(left)from the inferior vena 
cava (IVC) shows no more passage through the channel still visible 
between the septum primum (SP) to the right and the septum 
secundum (SS) to the left on the image. The Eustachian valve (EV) is 
visible both byﬂuoroscopy (small solid white arrows) and by 
echocardiography. Thelarge dotted yellow arrowsindicate the blood 
directed from the IVC onto the patent foramen ovale by the EV. LA
atrium; PFO¼patent foramen ovale; RA¼right atrium;
TEE¼transesophageal echocardiography.
showed  that
regardlessofthetypeofdevice
used,PFOclosurewasmore
efﬁcacious  than  medicalther-
apy  forpreventionofrecurrent
neurological  events(HR:  0.67;
95% CI: 0.44to1.00), with stronger beneﬁt when
onlyPCandRESPECT  were  pooled  (HR:0.54;95%
CI:0.29to1.01)inanintention-to-
treatanalysis(28).  Both  thePCand  RESPECT
trials  used  the  samePFOoccluder,which
justiﬁedpoolingthe data from thesetrials.
Subsequently, a patient-level meta-analysis of
CLOSURE I, PC, and RESPECT was published(30).
The study conﬁrmed that among 2,303 patients
with  a  cryptogenic  cerebrovascular  event,  PFO
closure  was  superior  to  medical  therapy  for
secondary  prevention  of  stroke  (HR:  0.58;
p¼0.043), with a more robust beneﬁt when the
PFO occluder of PC and RESPECT was used (HR:
0.39;  p¼0.013).  A  network  meta-analysis
including  a  trial  randomizing  between
d vices(31)conﬁrmed  that  use  of  this  PFO
occluder was the pref- erable technique for PFO
closure at that time(32).
CHANGE IN NORTH AMERICAN AND EUROPEAN 
STANCE
Followingthepositive   resultsofthe   meta-
analysesoftheﬁrst3trials  andthelong-term
follow-upoftheRESPECT trial, the U.S. Food and
Drug  Adminis-  tration  (FDA)  approved
thePFOoccluderusedinPCand
RESPECTonOctober  28,  2016.  This
approvalwasfor
percutaneousPFOclosureinpatients
103
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TABLE 1Clinical Trials Randomizing Cryptogenic Stroke Patients to Percutaneous PFO Closure or Medical Therapy
Randomized 
Clinical Trial (Ref. 
#)
Cohort 
(Number of 
Patients)
Device Arm Medical Arm Follow-Up PrimaryOutcome Results
CLOSURE I Cryptogenic stroke or 
TIAþ
PFO closureþaspirin and Aspirin, warfarin 
or
2yrs Compositeofstroke,TIA,PFOclosuredidnot
(20) PFO; age 18–60 
yrs(909)
warfarin for 1 month, both early  deathfromany signiﬁcantlyreduce
then aspirin for 2 yrs etiologyandlate recurrent stroke orTIA
neurologicaldeath compared withmedical
therapy
PC(23) Cryptogenic  stroke,
TIA  or  peripheral
embolismþPFO;
age<60 yrs (414)
PFO closureþaspirin for 5–Antiplatelet or
6 monthsþclopidogrelor
antithromboticticlopidine for1–
6months therapy
Mean4yrs Compositeofdeath, PFO closure didn o t
nonfatalstroke,TIA,
signiﬁcantlyreduceorperipheral
recurrentembolic
embolism events ordeath
compared with 
medical therapy
RESPECT( 27)
(extend
ed 
follow-
up)
Cryptogenic 
strokeþPFO; age 18–
60 yrs (980)
PFO closureþaspirin 
and clopidogrel for 1
month, then aspirin 
for 5 months
Aspirin, 
warfarin, 
clopidogrel or
aspirinþexten
ded release
dipyridamole
Median 5.9 yrs   Compositeo f recurrent PFO 
closurereduced
nonfatalandfatal recurrent 
strokeeventsstroke andearlydeath
compared 
withmedical
therapy
CLOSE(40) Cryptogenic 
strokeþPFO
PFO closureþaspirin and Aspirin, 
clopidogrel,
Mean5.3± Fatal or nonfatal stroke PFO closurereduced
with large shunt or 
atrial
clopidogrel for 3 
months,
or aspirinþ 2.0yrs recurrent
strokeevents
septal aneurysm; 
age
then single 
antiplatelet
extended-
release
compared with medical
16–60 yrs (663) therapy dipyridamole 
or
therapy
vitamin K
Author's Personal 
Copy antagonist ordirect oral
anticoagulant
Gore REDUCE Cryptogenic 
strokeþPFO;
PFO closureþaspirin, aspirin Aspirin, 
aspirin and
Median 3.2  yrs   Freedomfromstroke; PFO 
closurereduced
(41) age 18–59 yrs (664) and dipyridamole, or dipyridamole, 
or
incidence ofnewbrain recurrent strokeevents
clopidogrel clopidogrel infarctonMRI and new braininfarcts
on MRI compared with
medical therapy
MRI¼magnetic resonance imaging; PFO¼patent foramen ovale; TIA¼transient ischemic attack.
aged18  to  60yearswho  hadstrokes  from
presumedparadoxicalembolism  when  another
cause  could  notbedetermined  after  extensive
clinical  evaluationby  aneurologist  and
cardiologist(33).  The  FDA  concluded  that  the
device demonstratedareassuring levelofefﬁcacy
and  safety.  Applicable  specialtyorganiza-
tionsintheUnited  States  haveyet
toreacttothesedata  regarding  their
recommendations(34,35).Incontrast,as
ofNovember  2017,  the  Canadian  guide-  lines
were  updatedtorecommend  PFO
closurepluslong-term  antiplatelet  therapy
overlong-term  antithrombotictherapy
alone,inpatients  age18to  60years  with  recent
cryptogenic
strokesorTIAs(36).ThestanceinEurope had been
more  liberal  and  pro-  active  regarding  PFO
closure  for  more  thanadecadeinmost
countries(37),  except  for  the
UnitedKingdom(38).Itwasthought  that
therewasnoneed  for
adaptationofguidelinesinmost  countriesor
bytheEuropean Stroke Organization(39).
NEWERRANDOMIZEDTRIALS
THECLOSE TRIAL.CLOSE (Patent Foramen Ovale
ClosureorAnticoagulantsversus
AntiplateletTher-apytoPrevent  Stroke
Recurrence;NCT00562289)wasarandomized,
multicenter, open-label trial(with
blinded  adjudicationofoutcome
events)enrolling663patients  aged16  to
60yearswho  hadrecentstrokes  attributedtoPFO.
Only  patients  withassoci-ated  large  interatrial
shuntsoratrial  septal  aneu-  rysms  were
included.  Patients  eligible  for  all3armswere
randomizedin  a1:1:1   ratiototranscatheterPFO
closure
plusantiplatelettherapy,antiplatelettherapy
alone,ororalanticoagulation.Closureusingavariet
yof  11deviceswasdirectly  compared
withantiplatelet  therapyand
oralanticoagulation,andantiplatelettherapy  was
alsocomparedwithoral anticoagulation(40).
Atameanfollow-
upof5.3±2.0years,PFOclosurewassuperior,wit
halowerrateofrecurrentstroke(infactnostrokea
tall) compared with medicaltherapy
(0% vs. 6.0%; HR: 0.03;95% CI:0  to0.26;p<0.001).
Successful
closurewasdocumentedin93%ofpatientsonfollow
-up  echocardiography.  The  rateofproce-
duralcomplicationsfromPFOclosurewas5.9%.The
rewasnosigniﬁcant  differenceinserious  adverse
events
includingmajorbleedingcomparingclosurewithan
-
tiplatelettherapyalone(p>0.10)butatrialﬁbrillation
occurredatahigher
rateinthedevicearm(4.6%vs.0.9%;p¼0.02).Of11
casesofatrialﬁbrillationafterimplantationofdevic
es,10(91%)   occurredwithin1month
aftertheprocedure withnorecurrenceduring
JACCVOL.71,NO.9 ,2018 Mojadidietal.
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FIGURE 2Recurrent Stroke and Atrial Fibrillation/Flutter Outcomes in Cryptogenic Stroke Patients Randomized to PFO Closure or Medical Therapy
ARecurrent Stroke
Device Control RiskRatio Risk Ratio
Study or Subgroup Events Total Events Total Weight M–H, Random, 95% CI Year M–H, Random, 95% CI
CLOSE(40) 02 3 8 14 235 6.1% 0.03[0.00-0.57]2017
RESPECT(27) 184 9 9 28 481 32.2% 0.62 [0.35-1.11]2017
REDUCE(41) 6 441 12 223 24.1% 0.25[0.10-0.66]2017
PC(23) 12 0 4 5 210 9.5% 0.21[0.02-1.75]2013
CLOSUREI(20) 12447 13462 28.0% 0.95[0.44-2.07]2012
Author's Personal 
CopyTotal(95%CI) 1829 16111 0 0 . 0 % 0.42[0.20-0.91]
Totalevents 37 72
Heterogeneity:Tau2=0.38;Chi2=9.72,df=4(P=0.05);I2=59% 0.001 0.1 1 10 1000
Test for overall effect: Z = 2.22 (P = 0.03) Favors[Device] Favors[Control]
BAtrial Fibrillation/Flutter
Device Control RiskRatio Risk Ratio
Study or Subgroup Events Total Events Total Weight M–H, Random, 95% CI Year M–H, Random, 95% CI
CLOSE(40) 11238 2 235 19.0% 5.43 [1.22-24.24]2017
RESPECT(27) 74 9 9 4 481 25.5% 1.69[0.50-5.73]2017
REDUCE(41) 29 441 1 223 12.0% 14.66 [2.01-106.95]2017
PC(23) 6204 2 210 17.3% 3.09[0.63-15.12]2013
CLOSUREI(20) 23447 3462 26.2% 7.92[2.40-26.21]2012
Total(95%CI) 1829 16111 0 0 . 0 % 4.55[2.16-9.60]
Totalevents 76 12
Heterogeneity:Tau2=0.18;Chi2=5.33,df=4(P=0.26);I2=25% 0.001 0.1 1 10 1000
Test for overall effect: Z = 3.98 (P < 0.0001) Favors[Device] Favors[Control]
Summaryforestplotfortheefﬁcacyoutcomeofrecurrentstrokeandsafetyoutcomeofatrialﬁbrillation/ﬂutter.Therelativesizeofthedatamarkersindicatest
heweight ofthesamplesizefromeachstudy.ReprintedwithpermissionfromMojadidietal.
(42).CI¼conﬁdenceinterval;CLOSE¼PatentForamenOvaleClosureorAnticoagulants versus Antiplatelet Therapy to Prevent Stroke Recurrence; CLOSURE 
I¼Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient 
IschemicAttackduetoPresumedParadoxicalEmbolismthroughaPatentForamenOvale;M-H¼Mantel-
Haenszel;PC¼RandomizedClinicalTrialComparingtheEfﬁcacy 
ofPercutaneousClosureofPatentForamenOvale(PFO)WithMedicalTreatmentinPatientsWithCryptogenicEmbolism;PFO¼patentforamenovale;REDUCE¼G
ore Helex Septal Occluder/Gore Cardioform Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Conﬁrmed Transient 
IschemicAttackinPatientsWithPFO;RESPECT¼RandomizedEvaluationofRecurrentStrokeComparingPFOClosuretoEstablishedCurrentStandardofCare
Treatment.
a  median  follow-up  of  4.4  years.  Oral
anticoagulation  was  discontinued  in  70% (7  of
10) of these patients after a median of 6 months.
ResultsoftheCLOSE  trial
conﬁrmedtheearlyandlong-term  follow-up
dataofRESPECT,  wherepercu-taneous  PFO
closurewasassociated  withsigniﬁcantlyfewer
recurrent  strokesinpatients
withcryptogenicstrokewhohave  certain
echocardiographicfeatures(i.e.,presenceoflarge
shuntoratrialseptalaneurysm).THEGORE
REDUCE TRIAL.Gore  REDUCE(Gore
Helex    Septal    Occluder/Gore    
CardioformSeptal
Occluder and Antiplatelet Medical Management
for  ReductionofRecurrent  StrokeorImaging-
ConﬁrmedTIAinPatients  with  Patent  Foramen
Ovale  [PFO];NCT00738894)wasarandomized,
multicenter,open-label  trial  (with
blindedadjudicationofoutcome  events),
enrolling  664  patients,18  to
59yearsofage,withrecentcryptogenicstrokes,an
dwhohada PFO
documentedbyTEEbubble  study.  Patients  were
randomizedin  a2:1ratiotoundergo
percutaneousPFOclosure  with  the  Gore
HelexorCardioformseptaloccluders  (W.L.  Gore
and  Associates,  Flagstaff,Ari-zona)  plus
antiplatelet  therapyorantiplatelettherapy
alone.Theindex  ischemic
strokewaslabeledascryptogenic  after  other
recognizable  causesofstrokewere  ruled  out,
including  large-arteryatherosclerosis,small-
vessel  disease  (lacunar
infarct),establishedcardioembolic  cause
suchasatrialﬁbrillation,hypercoagulable
disorder  needing  anticoagulation,orarterial
dissection.Exclusionofthese  etiologieswasdone
with  extensive  cerebrovascular
imagingviacomputertomographyormagnetic
resonance  angi-
ography,ultrasonography,orcatheterangiograph
y.Inaddition,  patients  were  excludedifthey
hadstrongrisk  factors  for  other
mechanismsofstroke,  including  uncontrolled
hypertension, uncontrolleddiabetes,
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FIGURE 3PFO Occluders Used in Randomized Clinical Trials*
Author's Personal 
Copy
(A)TheSTARFlexPFOdevicewasusedinthedevicearmoftheCLOSUREItrial.
(B)TheAmplatzerPFOOccluderwasusedinthedevicearmof thePCandRESPECTtrials.
(C)TheGoreCardioformSeptalOccluderwas1of2devicesusedinthedevicearmoftheGoreREDUCEtrial.*The 
CLOSEtrialused11different PFOoccludingdevices.AbbreviationsasinFigure2.
autoimmune disease, or recent history of drug or 
alcohol use(41).
At  amedian  follow-upof3.2years,  recurrent
ischemic  stroke  occurred  less
frequentlyintheclosuregroup compared with the
medical therapy group(1.4%vs. 5.4%; HR: 0.23;
95% CI: 0.09to0.62;p¼0.002).
Also,therateofnewinfarctionsconﬁrmedbybrain
device  dependent.  The  increase  was
nonsigniﬁcant with the PFO occluder of  PC and
RESPECT (RR: 2.10; p¼0.13), but signiﬁcant with
the septal closure sys- tems used in CLOSURE I
(RR: 7.92; p<0.01), CLOSE (RR: 5.43; p¼0.027),
and Gore REDUCE (RR: 14.66;
p<0.01) devices(42).
SAFETY OF PERCUTANEOUS PFO CLOSURE
imagingwaslowerinthePFOclosurearmcompared                                                                                      
with the antiplatelet-only arm (5.7% vs. 11.3%;
risk  ratio  [RR]:  0.51;  95%  CI:  0.29  to  0.91;
p¼0.04).
Therewasnostatisticaldifferencein serious
adverse
events—including  major  bleeding,  between
closure  and
antiplatelettherapyalone(p>0.10).Yet,atrialﬁbrillation
occurred at a signiﬁcantly higher rate with PFO
closure (6.6% vs. 0.4%; p<0.001). Most cases of
post-device  implant  atrialﬁbrillation  (83%)
occurred within 45d a y s
afterclosure,and59%resolvedwithin2weeks.Of29pa-
tientswithatrialﬁbrillationorﬂutterintheclosurearm,1
had a recurrentstroke.
Results from the Gore REDUCE trial conﬁrmed
the  meta-analyses  of  earlier  trials,  long-term
follow-up data from RESPECT and CLOSE, where
transcatheter  PFO  closure  was  found  to  be
superior  to  medical  therapy  alone  in  patients
with cryptogenic stroke.
META-ANALYSIS OF ALL RANDOMIZED TRIALS
Astudy  levelmeta-
analysisofall5randomizedclinicaltrials(n¼3,440)
conﬁrmedthatpercutaneousPFOclosure
reducestheriskofrecurrent  stroke  compared
with  medical  therapy
(2.0%vs.4.5%;RR:0.42;95%CI:
0.20to0.91;p¼0.027).  However,  the  meta-
analysis  also  foundasigniﬁcantly
increasedriskofatrialﬁbrillationinpatients  with
devices(4.0%
vs.  0.7%;RR:4.55;95%  CI:2.16to9.60;p<0.01)
(Figure2).Theriskofatrialﬁbrillationwasfoundtobe
Anumberofdifferent PFO occluding devices have
been  implantedinthe  clinical  trials:
CLOSUREIusedanabandonedsystem;PCand
RESPECTthemarket-  leading
PFOoccluder;GoreREDUCE2generationsof
aproprietary  septal  occluder;  and
CLOSE11different devices (Figure3).
Observational  studies  have  reported  chest
painasanoccasional  complication  associated
withdeviceimplantation,  thoughtto
besecondaryto  anenhancedinﬂammatory
response,insome  casesduetonickel
allergy.ThePFOoccluderofPCandRESPECTcontain
s  more  nickel  than  other  devicesand
hasbeenhigh-lightedforthis
complication(43);however,PCandRESPECThadno
increased  chest  pain
eventsinthedevicearmcompared withthemedical
therapyarm(p¼NSforboth).Itshouldbenoted
thatanobserva-tional
surveyofcloseto14,000PFOdevice  implants
worldwide  reportedanincidenceof1
in500implantsresultinginsurgical removal, most
commonly dueto  severe,  persistentchest pain,
thoughtto  becausedbyallergy-induced
formationofexcessive  scar
tissuein50%ofcases(43).
Safety results from the clinical trials showed no
signiﬁcant difference in all-cause serious adverse
events  (including  major  bleeding)  when
comparing  percutaneous  PFO  closure  with
medical  therapy.  However, all  trials,  except  for
PC and RESPECT, had a
Author's Personal 
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signiﬁcantly  higher
incidenceofatrialﬁbrillationinthe  device  arm.
Most  casesofatrialﬁbrillationinthe
trialsoccurredearly(<45days)afterimplantationa
ndconsistedofasingleparoxysmal
episodethatresolved
spontaneously, medically, or with cardioversion.
Only  3.8%  of  postclosure  atrialﬁbrillation
episodes  report-  edly  progress  to  permanent
atrialﬁbrillation(44).
Theno-longer-
availabledeviceofCLOSUREIhadpreviously  been
associated  withthehighest  inci-
denceofsigniﬁcant  devicethrombosis,with  3.6%
versus0%with  septal  occludersofPC,
RESPECT,orGoreREDUCE(45).
Atrialﬁbrillationwasalso
mostcommonwiththedevicesofGoreREDUCEwith
6.6%,whichwashigher  than
expectedfrompreviousobservational
studies(44,45),  followedby
thedeviceofCLOSUREIwith  5.7%andthe
deviceofPC  andRESPECT  with
1.8%(20,23,27,41,42).
CONCLUSIONS: FUTURE GUIDELINES
Basedonthe  patient-level  meta-
analysisoftheﬁrst3randomized  trials(30),  the
CLOSE(40),RESPECT(extended  follow-up)
(26),andGore  REDUCE(41)trials,andthe  meta-
analysisofall5randomizedtrials(42),  PFO-
occluding  devices  decreasetheriskofrecurrent
stroke  compared  with  medical
therapyinpatients with cryptogenic stroke. Also,
basedonsub-
groupanalysesoftheRESPECTtrial(26,27),efﬁcacy
of
PFOclosureforpreventionofstrokeisenhancedinth
ose  patients  with  certain  echocardiographic
fea-  tures  (i.e.,  atrial  septal
aneurysmorlargeshunt).
Reasons   forthediscrepancy
betweentheearlier  numerically
positivebutstatistically  not  signiﬁcant
randomized  dataandmorerecent  signiﬁcantly
positive  trialsmustbemultifactorial.Weattribute
this  largelytoinclusionofpatients  with  index
strokes  more  likely
secondarytoparadoxicalembolismorhigher-risk
PFOsin  the3newlypub-lished  trials.  Gore
REDUCEhadvery  strict  exclusion  criteriatoomit
patients with other causesofstroke,suchaslarge-
artery  atherosclerotic  diseaseandsmall-  vessel
disease  (lacunar  infarcts),
basedonextensivecerebrovascularimaging.Italso
excludedpatientswith  uncontrolled  risk  factors.  CLOSE
onlyincludedpatients
withechocardiographicfeaturessuggestiveofgreater  potential
beneﬁt with closure (atrial septal aneurysmorlarge shunt); this
could  explain  the  remarkable  outcomeofzero  recurrent
strokesinthedevicearmduring5years.  Although  RESPECT  also
used  strict  inclusion  criteriaforselecting  patients   with
cryptogenic  stroke,  the  early  negative
resultsmaybeexplainedby
averylowfrequencyofrecurrentstroke(1%  peryear).
However,therateofrecurrentstrokewascontinuous  over
the10yearsobserved,
Author's Personal 
Copyandthusthebeneﬁt  with  device
closure  becamesig-niﬁcant  with
longer follow-up. Although there
areno  randomizeddata
beyond10years,
thereisnoreasontobelieve  that
this  protective  beneﬁt  will  not
persist.Thelessons learned from
all5trials  have
allowedtherecognitionofa“purer”
patient
populationatgreaterriskofrecurre
nt  paradoxical  embolism.
Strictexclu-
sionofotherdetectablecausesofst
rokeaidsin
therecognitionofpatientswhomos
t  likely  haveischemicstroke
associated  with  PFO.Insuch
patients,achangeinguidelinestor
ecommend
percutaneousPFOclosureasﬁrst-
line therapymay bewarranted.
Although  there  is  a
pathophysiological  rationale  for
the use of oral anticoagulants to
prevent  recurrent  paradoxical
embolism,  there  is  a  paucity  of
data  showing  superiority  or
comparativeness  of  anti-
coagulation  compared  with  PFO
closure or  anti-  platelets(9).  The
CLOSE  trial  demonstrated  a
nonsigniﬁcant 56% lower risk  of
stroke when oral anticoagulation
was used instead of antiplatelet
ther- apy. As anticoagulation was
contraindicated  in  numerous
patients,  the  study  was
underpowered  in  this  respect(46).  Until  a
randomized trial is performed comparing efﬁcacy
and  safety  of  oral  anticoagulation  versus  PFO
closure  in  patients  with  PFO-associated
cryptogenic stroke, percutaneous PFO closure is
to be considered the most effective and safest
option  to  reduce  the  risk  of  recurrent  stroke,
according to evidence-based randomized data.
The  clinical  trials  demonstrated
thattranscatheterPFOclosureissafe,
withnodifferenceinseriousadverse  events
compared  with  medical  therapy,   exceptfor
theriskofatrialﬁbrillation  afterimplan-
tationofthedevice.  Giventhepotentialofearlyun-
detected
atrialﬁbrillationasanetiologyofstroke,and
theadded  riskofpost-closureatrialﬁbrillation,it
isrecommendedtouse
prolonged($30days)cardiacmonitoringtostringe
ntly  avoid  undiagnosedatrialﬁbrillation.
Although  extended  cardiac
monitoringissuperiorto24-h  monitoringtodetect
atrialﬁbrillationinpatients  with  stroke
thatissuspectedto  becryp-togenic(47,48),
thiswas  notaninclusion  criterionin  any  of
the5cryptogenic  stroke
trials.Furtherresearchisneededtobetter
understand  thelong-termprognostic
outcomesofatrialﬁbrillationafterdeviceimplantat
ion.Atpresent,  these  long-
termprognosticoutcomesareunknown.
The
pathwaytomanagingandlabelingapatient’s
strokeasrelatedto  aPFOshould
involveamultidisciplinary  team
includinganeurologist,  cardiologist,andother
healthprofessionalstrainedin  thecareofpatients
with  stroke.  The  initialdiagnosisofcryptogenic
strokeismadeby  aneurologist;car-
diologistsshoulddocumentthePFOandensurethat
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CENTRAL ILLUSTRATIONEvidence-Based Algorithm for PFO Closure in Ischemic Stroke Patients for Highest 
Clinical Yield, Based on Randomized Trials
Biological age ≤60 
years ischemic 
stroke, and PFO
•Largeartery •Uncontrolled • Atrialfibrillationor
•<1yearoflifeexpectancyatherosclerosis hypertension
flutter(ideally •End-stageheart,liver,
• Cardioembolicsource • Uncontrolled ≥30-daycardiac lung, 
or kidneydisease
• Smallvesseldisease No diabetes No monitoring)No • 
Cardiactumor
• Arterialdissection •Autoimmunedisease • 
Endocarditis orsepticemia
Author's Personal 
Copy•Hypercoagulable • Drug oralcoholabuse • Severe 
valvularpathologydisorder
Yes Yes Yes Yes No
Medical 
therapyPercutaneous 
PFO closure
Enhanced reasons for PFO
closure:
• Prior venousthromboembolism
• Multifocal cerebraldefects
• LargePFO
• Atrial septalaneurysm
• Eustachianvalveor Chiarinetwork
Mojadidi, M.K. et al. J Am Coll Cardiol. 2018;71(9):1035–43.
Patients can expect the greatest beneﬁt from percutaneous PFO closure if they have no other cardiovascular stroke causes on 
imaging/laboratory analyses, no uncontrolled risk factors, no atrialﬁbrillation orﬂutter, and no poor prognostic markers. PFO¼patent 
foramen ovale.
cardiovascular  culprits  and  uncontrolled
riskfactorshave  been  ruledoutwhen
recommendingPFO  closure.
Counselingbeforeclosure  should
includediscussionofindividualized
risksoftheprocedurebasedoncomorbiditiesanda
discussionofthe  atrial  septal  anatomy  and
degreeofright-to-leftshunting  (Central
Illustration).Weadvocateformultidisci-plinary
cryptogenic  stroke  teamstofacilitate  this
pathway. This ensures that PFO closureisrecom-
mendedfor  allpatientswhohave  stroke
fromnoother likelysource.
Therelative
safetyandsimplicityofpercutaneousPFOclosure
andtheproven  protection
againststrokeopenanavenueoffurther
indicationsforPFOclosure,suchas
inthepresenceofotherpotentialcausesofstrokeor
evenasprimary  preventionofstrokeinhigh-
riskpersons.
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